Very low-dose radiotherapy for extranodal marginal zone lymphoma of bronchus-associated lymphoid tissue

References

• Sammassimo S, Pruneri G, Andreola G, et al. A retrospective international study on primary extranodal marginal zone lymphoma of the lung (BALT lymphoma) on behalf of international extranodal lymphoma study group (IELSG). Hematol Oncol. 2016;34(4):177–183. doi:10.1002/hon.2243
   PubMed Web of Science ®Google Scholar
• Oh SY, Kim WS, Kim JS, et al. Pulmonary marginal zone B-cell lymphoma of MALT type–what is a prognostic factor and which is the optimal treatment, operation, or chemotherapy?: consortium for improving survival of lymphoma (CISL) study. Ann Hematol. 2010;89(6):563–568. doi:10.1007/s00277-009-0875-7
   PubMed Web of Science ®Google Scholar
• Zucca E, Arcaini L, Buske C, et al. Marginal zone lymphomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31(1):17–29. doi:10.1016/j.annonc.2019.10.010
   PubMed Web of Science ®Google Scholar
• Stefanovic A, Morgensztern D, Fong T, et al. Pulmonary marginal zone lymphoma: a single Centre experience and review of the SEER database. Leuk Lymphoma. 2008;49(7):1311–1320. doi:10.1080/10428190802064933
   PubMed Web of Science ®Google Scholar
• Joffe E, Leyfman Y, Drill E, et al. Active surveillance of primary extranodal marginal zone lymphoma of bronchus-associated lymphoid tissue. Blood Adv. 2021;5(2):345–351. doi:10.1182/bloodadvances.2020003213
   PubMed Web of Science ®Google Scholar
• Troch M, Streubel B, Petkov V, et al. Does MALT lymphoma of the lung require immediate treatment? An analysis of 11 untreated cases with long-term follow-up. Anticancer Res. 2007;27:3633–3637.
   PubMed Web of Science ®Google Scholar
• Borie R, Wislez M, Thabut G, et al. Clinical characteristics and prognostic factors of pulmonary MALT lymphoma. Eur Respir J. 2009;34(6):1408–1416. doi:10.1183/09031936.00039309
   PubMed Web of Science ®Google Scholar
• Wöhrer S, Kiesewetter B, Fischbach J, et al. Retrospective comparison of the effectiveness of various treatment modalities of extragastric MALT lymphoma: a single-center analysis. Ann Hematol. 2014;93(8):1287–1295. doi:10.1007/s00277-014-2042-z
   PubMed Web of Science ®Google Scholar
• Lee H, Yang B, Nam B, et al. Treatment outcomes in patients with extranodal marginal zone B-cell lymphoma of the lung. J Thorac Cardiovasc Surg. 2017;154(1):342–349. doi:10.1016/j.jtcvs.2017.03.043
   PubMed Web of Science ®Google Scholar
• Xu Y, Zheng M, Guo Q, et al. Clinical features and survival outcome of Early-Stage primary pulmonary MALT lymphoma after surgical treatment. Front Surg. 2021;8:713748. doi:10.3389/fsurg.2021.713748
   PubMed Web of Science ®Google Scholar
• Wang L, Ye G, Liu Z, et al. Clinical characteristics, diagnosis, treatment, and prognostic factors of pulmonary mucosa-associated lymphoid tissue-derived lymphoma. Cancer Med. 2019;8(18):7660–7668. doi:10.1002/cam4.2683
   PubMed Web of Science ®Google Scholar
• Zhao S, Zhang L, Gu Z, et al. Clinical manifestations of pulmonary mucosa-associated lymphoid tissue lymphoma: single-center experience with 18 patients. Onco Targets Ther. 2018;11:555–561. doi:10.2147/OTT.S147275
   PubMed Web of Science ®Google Scholar
• Girinsky T, Paumier A, Ferme C, et al. Low-dose radiation treatment in pulmonary mucosa-associated lymphoid tissue lymphoma: a plausible approach? A single-institution experience in 10 patients. Int J Radiat Oncol Biol Phys. 2012;83(3):e385-389–e389. doi:10.1016/j.ijrobp.2012.01.005
   Web of Science ®Google Scholar
• Hashemi SMS, Heitbrink MA, Jiwa M, et al. A patient with endobronchial BALT lymphoma successfully treated with radiotherapy. Respir Med. 2007;101(10):2227–2229. doi:10.1016/j.rmed.2006.11.028
   PubMed Web of Science ®Google Scholar
• Demir M, Güven DC, Kiliçkap S. Same disease, different approaches: a report on six lymphoma cases with extranodal marginal zones in rare sites. J Oncol Sci. 2021;7(1):34–38. doi:10.37047/jos.2020-79452
   Google Scholar
• Hoskin PJ, Kirkwood AA, Popova B, et al. 4 Gy versus 24 Gy radiotherapy for patients with indolent lymphoma (FORT): a randomised phase 3 non-inferiority trial. Lancet Oncol. 2014;15(4):457–463. doi:10.1016/S1470-2045(14)70036-1
   PubMed Web of Science ®Google Scholar
• Cerrato M, Orlandi E, Vella A, et al. Efficacy of low-dose radiotherapy (2 Gy × 2) in the treatment of marginal zone and mucosa-associated lymphoid tissue lymphomas. Br J Radiol. 2021;94(1123):20210012. doi:10.1259/bjr.20210012
   PubMed Web of Science ®Google Scholar
• Imber BS, Chau KW, Lee J, et al. Excellent response to very-low-dose radiation (4 Gy) for indolent B-cell lymphomas: is 4 Gy suitable for curable patients? Blood Adv. 2021;5(20):4185–4197. doi:10.1182/bloodadvances.2021004939
   PubMed Web of Science ®Google Scholar
• Chelius M, Chau K, Yang J, et al. Low grade, indolent lymphomas of the head and neck: comparative toxicity of standard versus very low dose radiation therapy. Hematol Oncol. 2021;39(3):304–312. doi:10.1002/hon.2865
   PubMed Web of Science ®Google Scholar
• Hoskin P, Popova B, Schofield O, et al. 4 Gy versus 24 Gy radiotherapy for follicular and marginal zone lymphoma (FoRT): long-term follow-up of a multicentre, randomised, phase 3, non-inferiority trial. Lancet Oncol. 2021;22(3):332–340. doi:10.1016/S1470-2045(20)30686-0
   PubMed Web of Science ®Google Scholar
• Teckie S, Qi S, Chelius M, et al. Long-term outcome of 487 patients with early-stage extra-nodal marginal zone lymphoma. Ann Oncol. 2017;28(5):1064–1069. doi:10.1093/annonc/mdx025
   PubMed Web of Science ®Google Scholar
• Yahalom J, Illidge T, Specht L, et al. Modern radiation therapy for extranodal lymphomas: field and dose guidelines from the international lymphoma radiation oncology group. Int J Radiat Oncol Biol Phys. 2015;92(1):11–31. doi:10.1016/j.ijrobp.2015.01.009
   PubMed Web of Science ®Google Scholar
• Lowry L, Smith P, Qian W, et al. Reduced dose radiotherapy for local control in non-Hodgkin lymphoma: a randomised phase III trial. Radiother Oncol. 2011;100(1):86–92. doi:10.1016/j.radonc.2011.05.013
   PubMed Web of Science ®Google Scholar
• Younes A, Hilden P, Coiffier B, et al. International working group consensus response evaluation criteria in lymphoma (RECIL 2017). Ann Oncol. 2017;28(7):1436–1447. doi:10.1093/annonc/mdx097
   PubMed Web of Science ®Google Scholar
• Zafar SY, Abernethy AP. Financial toxicity, part I: a new name for a growing problem. Oncology (Williston Park). 2013;27(80–81):149.
   PubMedGoogle Scholar
• Ng AK, Yahalom J, Goda JS, et al. Role of radiation therapy in patients with relapsed/refractory diffuse large B-Cell lymphoma: guidelines from the international lymphoma radiation oncology group. Int J Radiat Oncol Biol Phys. 2018;100(3):652–669. doi:10.1016/j.ijrobp.2017.12.005
   PubMed Web of Science ®Google Scholar
• Twyman-Saint Victor C, Rech AJ, Maity A, et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature. 2015;520(7547):373–377. doi:10.1038/nature14292
   PubMed Web of Science ®Google Scholar
• Hubbeling H, Silverman EA, Michaud L, et al. Bridging radiation rapidly and effectively cytoreduces High-Risk relapsed/refractory aggressive B cell lymphomas prior to chimeric antigen receptor T cell therapy. Transplant Cell Ther. 2023;29(4):259.e1–259.e10. doi:10.1016/j.jtct.2022.12.021
   PubMedGoogle Scholar
• Qu C, Ping N, Kang L, et al. Radiation priming chimeric antigen receptor T-Cell therapy in relapsed/refractory diffuse large B-Cell lymphoma with high tumor burden. J Immunother. 2020;43(1):32–37. doi:10.1097/CJI.0000000000000284
   PubMed Web of Science ®Google Scholar
• Pinnix CC, Gunther JR, Dabaja BS, et al. Bridging therapy prior to axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma. Blood Adv. 2020;4(13):2871–2883. doi:10.1182/bloodadvances.2020001837
   PubMed Web of Science ®Google Scholar
• Wright CM, LaRiviere MJ, Baron JA, et al. Bridging radiation therapy before commercial chimeric antigen receptor T-Cell therapy for relapsed or refractory aggressive B-Cell lymphoma. Int J Radiat Oncol Biol Phys. 2020;108(1):178–188. doi:10.1016/j.ijrobp.2020.05.014
   PubMed Web of Science ®Google Scholar
• Sim AJ, Jain MD, Figura NB, et al. Radiation therapy as a bridging strategy for CAR T cell therapy with axicabtagene ciloleucel in diffuse large B-Cell lymphoma. Int J Radiat Oncol Biol Phys. 2019;105(5):1012–1021. doi:10.1016/j.ijrobp.2019.05.065
   PubMed Web of Science ®Google Scholar
• Imber B, Palomba ML, DeSelm C, et al. MSKCC early experience using radiotherapy as a bridging strategy for relapsed diffuse large B cell lymphoma before CD19 CAR T therapy. Blood. 2019;134(Supplement_1):3238–3238. doi:10.1182/blood-2019-131449
   Google Scholar
• Jacobson CA, Chavez JC, Sehgal AR, et al. Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial. Lancet Oncol. 2022;23(1):91–103. doi:10.1016/S1470-2045(21)00591-X
   PubMed Web of Science ®Google Scholar
• Fowler NH, Dickinson M, Dreyling M, et al. Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial. Nat Med. 2022;28(2):325–332. doi:10.1038/s41591-021-01622-0
   PubMed Web of Science ®Google Scholar